Nuo Therapeutics, Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Steven A Shallcross. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Steven A Shallcross has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TOVX / Theriva Biologics, Inc. CEO and CFO, Director 250,000
US:ELYS / Elys BMG Group, Inc. Director 27,717
US:VEEE / Twin Vee Powercats Co. Director 5,500
US:CMXI / Chief Financial Officer 79,500
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Steven A Shallcross. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AURX / Nuo Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AURX / Nuo Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2014-08-26 CMXI SHALLCROSS STEVEN A 27,500 0.3800 27,500 0.3800 10,450 731
2014-08-20 CMXI SHALLCROSS STEVEN A 52,000 0.3900 52,000 0.3900 20,280

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AURX / Nuo Therapeutics, Inc. Insider Trades
Insider Sales AURX / Nuo Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AURX / Nuo Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AURX / Nuo Therapeutics, Inc. Insider Trades
Insider Purchases ELYS / Elys BMG Group, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AURX / Nuo Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELYS / Elys BMG Group, Inc. Insider Trades
Insider Sales ELYS / Elys BMG Group, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AURX / Nuo Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELYS / Elys BMG Group, Inc. Insider Trades
Insider Purchases TOVX / Theriva Biologics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AURX / Nuo Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-06-07 TOVX SHALLCROSS STEVEN A 14,000 0.6931 560 17.3275 9,703 23 1.0000 -9,143 -94.23
2023-06-06 TOVX SHALLCROSS STEVEN A 26,000 0.6328 1,040 15.8200 16,453
2023-02-10 TOVX SHALLCROSS STEVEN A 25,000 1.0430 1,000 26.0750 26,075
2023-02-02 TOVX SHALLCROSS STEVEN A 25,000 0.9405 1,000 23.5125 23,512
2023-01-25 TOVX SHALLCROSS STEVEN A 25,000 0.8730 1,000 21.8250 21,825
2023-01-20 TOVX SHALLCROSS STEVEN A 25,000 0.7482 1,000 18.7050 18,705
2022-12-29 TOVX SHALLCROSS STEVEN A 100,000 0.4370 4,000 10.9250 43,700
2021-05-10 SYN SHALLCROSS STEVEN A 50,000 0.4919 5,000 4.9190 24,595
2019-08-23 SYN SHALLCROSS STEVEN A 50,000 0.4157 5,000 4.1570 20,785

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TOVX / Theriva Biologics, Inc. Insider Trades
Insider Sales TOVX / Theriva Biologics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AURX / Nuo Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TOVX / Theriva Biologics, Inc. Insider Trades
Insider Purchases VEEE / Twin Vee Powercats Co. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AURX / Nuo Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VEEE / Twin Vee Powercats Co. Insider Trades
Insider Sales VEEE / Twin Vee Powercats Co. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AURX / Nuo Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VEEE / Twin Vee Powercats Co. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Steven A Shallcross as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-06-08 2023-06-07 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 14,000 250,000 5.93 0.69 9,703 173,275
2023-06-07 2023-06-06 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 26,000 236,000 12.38 0.63 16,453 149,341
2023-02-16 2023-02-14 4 ELYS Elys Game Technology, Corp.
Common Stock
A - Award 22,472 27,717 428.45 0.89 20,000 24,668
2023-02-13 2023-02-10 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 25,000 210,000 13.51 1.04 26,075 219,030
2023-02-03 2023-02-02 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 25,000 185,000 15.62 0.94 23,512 173,992
2023-01-26 2023-01-25 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 25,000 160,000 18.52 0.87 21,825 139,680
2023-01-23 2023-01-20 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 25,000 135,000 22.73 0.75 18,705 101,007
2023-01-03 2022-12-29 4 TOVX Theriva Biologics, Inc.
Common Stock
P - Purchase 100,000 110,000 1,000.00 0.44 43,700 48,070
2021-12-27 2021-12-23 4 SYN Synthetic Biologics, Inc.
Stock Options (right to buy)
A - Award 650,000 650,000
2021-09-15 2021-09-13 4 ELYS Elys Game Technology, Corp.
Stock Option(right to buy)
A - Award 13,600 13,600
2021-07-26 2021-07-23 4 VEEE Twin Vee PowerCats, Co.
Stock Options
A - Award 5,500 5,500
2021-05-10 2021-05-10 4 SYN Synthetic Biologics, Inc.
Common Stock
P - Purchase 50,000 100,000 100.00 0.49 24,595 49,190
2021-01-27 2021-01-22 4 NWGI Elys Game Technology, Corp.
Common Stock
A - Award 5,245 5,245 5.72 30,001 30,001
2020-12-31 2020-12-30 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 450,000 450,000
2020-10-05 2020-10-01 4 NWGI Newgioco Group, Inc.
Stock Option
A - Award 35,000 35,000
2019-12-05 2019-12-04 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 450,000 450,000
2019-08-26 2019-08-23 4 SYN Synthetic Biologics, Inc.
Common Stock
P - Purchase 50,000 50,000 0.42 20,785 20,785
2019-07-08 2019-07-05 4 NWGI Newgioco Group, Inc.
Stock Option
A - Award 2,500 82,500 3.12
2019-07-08 2019-07-05 4/A NWGI Newgioco Group, Inc.
Stock Option
A - Award 82,500 82,500
2018-12-07 2018-12-06 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 200,000 200,000
2017-12-21 2017-12-20 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 550,000 550,000
2016-12-02 2016-11-30 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 500,000 500,000
2015-12-04 2015-12-04 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 100,000 100,000
2015-06-01 2015-06-01 4 SYN Synthetic Biologics, Inc.
Stock Options
A - Award 900,000 900,000
2014-08-27 2014-08-26 4 CMXI CYTOMEDIX INC
Common Stock
P - Purchase 27,500 79,500 52.88 0.38 10,450 30,210
2014-08-21 2014-08-20 4 CMXI CYTOMEDIX INC
Common Stock
P - Purchase 52,000 52,000 0.39 20,280 20,280
2014-06-20 2014-04-08 4/A CMXI CYTOMEDIX INC
OPTIONS TO PURCHASE SHARES OF COMMON STOCK
A - Award 300,000 900,000 50.00
2014-04-10 2014-04-08 4 CMXI CYTOMEDIX INC
OPTIONS TO PURCHASE SHARES OF COMMON STOCK
A - Award 1,219,900 1,819,900 203.32
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)